文献速递药物相互作用药物不良反应与药物警戒

SGLT-2抑制剂与他汀类药物的药物相互作用与肌病风险:基于不良事件报告数据的失衡分析

Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.
PubMed 文献 · Drug Saf · 2022-03-05

该研究利用美国FDA不良事件报告系统(FAERS)数据,纳入688,388份至少记录一种降糖药的报告(其中9.80%含SGLT-2i),比较单用SGLT-2i、单用他汀、两者联用及均不用者中肌病报告比例的失衡情况。结果显示,联用SGLT-2i与他汀者的肌病报告并未较单用他汀者出现不成比例升高。

要点

  • 联用SGLT-2i与他汀的肌病报告比值比为2.95(95%CI 2.27-3.85),低于单用他汀的6.41(95%CI 5.86-7.02)。
  • 全部纳入报告中肌病病例共2202例,其中61.26%发生在单用他汀者,仅2.72%发生在SGLT-2i与他汀联用者。
  • 在药物类别层面,未发现联用SGLT-2i与他汀导致肌病报告不成比例升高,但单个药物层面仍需进一步观察性研究。

核心结论

  • 在药物类别层面,联用SGLT-2i与他汀者的肌病报告并未较单用SGLT-2i或单用他汀者出现不成比例升高。
  • 作者提出,仍需进一步开展观察性研究,以在单个药物层面更好地评估这一相互作用。

研究设计与样本

  • 研究为基于美国FDA不良事件报告系统(FAERS)数据的失衡分析(disproportionality analysis)。
  • 纳入标准为报告中至少记录一种降糖药,共纳入688,388份报告,其中9.80%含至少一种SGLT-2i。
  • 比较均不用SGLT-2i或他汀、单用SGLT-2i、单用他汀、两者联用四组中肌病病例与非病例的比例,并计算报告比值比及95%置信区间。
  • 进一步按单个SGLT-2i及选定他汀(瑞舒伐他汀或阿托伐他汀)进行分层分析。

主要发现

  • 共2202例肌病病例,其中61.26%发生在单用他汀者,仅2.72%发生在SGLT-2i与他汀联用者。
  • 联用SGLT-2i与他汀者的肌病报告比值比为2.95(95%CI 2.27-3.85)。
  • 单用他汀者的肌病报告比值比为6.41(95%CI 5.86-7.02)。

临床怎么用

  • 提示临床在类别层面不必因联用SGLT-2i与他汀而过度担忧肌病报告风险升高。
  • 对具体SGLT-2i与具体他汀联用的个体化风险评估,仍需结合更多观察性研究证据。

局限性

  • 研究基于自发报告数据(FAERS),存在报告偏倚及混杂因素等失衡分析的固有局限。
  • 按单个SGLT-2i及选定他汀(瑞舒伐他汀或阿托伐他汀)的分层结果在摘要中未给出具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: An increased risk of myopathy due to a potential interaction between sodium glucose co-transporter-2 inhibitors (SGLT-2i) and HMG-CoA reductase inhibitors (statins) has been suggested by case reports. OBJECTIVE: We aimed to assess if the reporting of myopathy is disproportionally higher among people using both SGLT-2i and statins compared to using either SGLT-2i or statins alone. METHODS: We conducted a disproportionality analysis using data from the US Food and Drug Administration Adverse Event Reporting System (FAERS). We included reports with at least one antihyperglycemic agent. We compared the proportion of myopathy cases to non-cases between those not using SGLT-2i or statins, using SGLT-2i only, statins only, or both. We calculated the reporting odds ratio and 95% confidence interval. We further stratified by individual SGLT-2i and selected statins (rosuvastatin or atorvastatin). RESULTS: We included 688,388 reports with at least one antihyperglycemic agent recorded, of which 9.80% had at least one SGLT-2i agent. Among all included reports, there were a total of 2202 myopathy cases with the majority, 61.26%, occurring among those using statins alone and only 2.72% of myopathy cases were among those using both SGLT-2i and statins together. Reporting of myopathy was not disproportionally higher among those reporting the use of SGLT-2i with statins (reporting odds ratio 2.95, 95% confidence interval 2.27-3.85) compared to statins alone (reporting odds ratio 6.41, 95% confidence interval 5.86-7.02). CONCLUSIONS: Reports of myopathy were not disproportionally higher among those using SGLT-2i with statins compared to SGLT-2i or statins alone at the class level. Further observational studies may be needed to better assess this interaction at the agent level.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Alkabbani W, Pelletier R, Beazely MA, et al. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Saf. 2022. PMID: 35247195. doi:10.1007/s40264-022-01166-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。